Evidence map›Paper›PMID 32364032›Full record

ArticleJournal of medical economics2020

Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.

Gihan Hamdy Elsisi, Mohammed Moustapha Anwar, Mohamed Khattab, Ibrahim Elebrashy, Alaa Wafa, Hemat Elhadad, Mohamad Awad, João L Carapinha

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Journal of medical economics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04385589. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04385589 phase4completed

Safety and Efficacy of Adding Dapagliflozin and Furosemide in Diabetic Patients (Type 2) With Decompensated Heart Failure With Reduced Ejection Fraction (HFrEF)

Ran2020Enrolled100Registered outcomes4Posted comparisons0ConditionsHeart FailureArmsdapagliflozin, Insulin
PMID 32360273PMID 32377235PMID 32361851other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gihan Hamdy ElsisiHTA Office, LLC, Cairo, Egypt.ORCID http://orcid.org/0000-0002-2917-9388
Mohammed Moustapha AnwarHTA Office, LLC, Cairo, Egypt.
Mohamed KhattabFaculty of Medicine, Cairo University, Giza, Egypt.
Ibrahim ElebrashyFaculty of Medicine, Cairo University, Giza, Egypt.
Alaa WafaFaculty of Medicine, Elmansoura University, Elmansoura, Egypt.
Hemat ElhadadFaculty of Medicine, Cairo University, Giza, Egypt.
Mohamad AwadFaculty of Medicine, Elzagazig University, Elzagazig, Egypt.
João L CarapinhaC&C, Inc., School of Pharmacy, Northeastern University, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Benzhydryl CompoundsBudgetsCardiovascular DiseasesCost-Benefit AnalysisDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsEgyptGlucosidesHumansHypoglycemic AgentsInsulinMetforminModels, EconomicRenal InsufficiencySulfonylurea CompoundsThiazolidinediones2,4-thiazolidinedioneBenzhydryl CompoundsdapagliflozinDipeptidyl-Peptidase IV InhibitorsGlucosidesHypoglycemic AgentsInsulinMetforminSulfonylurea CompoundsThiazolidinedionesbudget impact analysisconventional therapiesDapagliflozinEgyptH51I13type 2 diabetes

Identifiers

PMID32364032

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.